BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260504
DTEND;VALUE=DATE:20260506
DTSTAMP:20260422T122641
CREATED:20251206T101622Z
LAST-MODIFIED:20260125T043207Z
UID:9626-1777852800-1778025599@thebiocalendar.com
SUMMARY:TRI-CON 2026
DESCRIPTION:Join us for an exclusive gathering of senior-level investors\, pharma executives\, entrepreneurs\, research thought leaders\, and innovators at the 33rd Annual TRI-CON. Connect with investors and partners at intimate networking sessions; gain strategic insights on funding activities\, business development\, and innovation strategies in diagnostics\, precision medicine\, and AI from industry-led panels; and hear candid perspectives and business recommendations from key opinion leaders during dynamic fireside chats. Building on a 30+ track record\, TRI-CON is positioned as the premier meeting place for key stakeholders to foster meaningful connections\, acquire valuable strategic insights\, and drive innovation and collaboration. Returning to San Francisco in 2026!
URL:https://thebiocalendar.com/event/tri-con-2026/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Featured,Investor,Networking,Partnering,Presentation,Summit
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/01/tric-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260504
DTEND;VALUE=DATE:20260508
DTSTAMP:20260422T122641
CREATED:20260327T140336Z
LAST-MODIFIED:20260327T140336Z
UID:10105-1777852800-1778198399@thebiocalendar.com
SUMMARY:SynBioBeta 2026
DESCRIPTION:Join our SynBioBeta community for three days of high-signal talks\, curated 1:1 meetings\, real partnering\, and hands-on exposure at the frontier of biology and technology. \nGo deep on AI-driven biology and therapeutics. You’ll also get up to speed on sustainable biomanufacturing of chemicals\, materials\, food\, and consumer products\, and discover applications of biology that you never thought possible. \nThis is where global builders\, backers\, and scouts have mind-blowing conversations and find their next moves.
URL:https://thebiocalendar.com/event/synbiobeta-2026/
LOCATION:San Jose\, San Jose\, CA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260504T110000
DTEND;TZID=America/Los_Angeles:20260504T120000
DTSTAMP:20260422T122641
CREATED:20260326T132035Z
LAST-MODIFIED:20260326T132035Z
UID:10076-1777892400-1777896000@thebiocalendar.com
SUMMARY:The Shift to High Concentration mAbs: 3 Critical UF/DF Challenges and How to Solve Them
DESCRIPTION:A practical look at overcoming viscosity\, fouling\, and aggregation with modern TFF platforms. \nAs monoclonal antibody therapies continue to evolve\, the industry is rapidly shifting from traditional mAb formulations to high‑concentration mAbs to enable subcutaneous delivery\, improve patient convenience\, and support next‑generation therapeutics. While this shift delivers clear clinical benefits\, it also introduces new risks and complexities particularly during ultrafiltration and diafiltration (UF/DF). \nIn this webinar\, we’ll examine how increasing protein concentration fundamentally changes UF/DF behavior—and why legacy approaches often struggle as viscosity rises and operating windows narrow. We’ll break down the three most critical UF/DF challenges associated with high‑concentration mAbs and discuss practical strategies to address them using modern TFF platforms. \nKey topics include:\n –   Why the industry is shifting toward high‑concentration mAbs—and what this means for downstream bioprocessing\n –   The three critical UF/DF challenges at high concentration:\n     ~     Managing viscosity and its impact on flux\, pressure\, and process control\n     ~     Preventing fouling and polarization that limit performance and scalability\n     ~     Reducing aggregation risk during concentration and diafiltration\n –   How modern\, automated TFF system design can help mitigate these risks\n –   What to consider when adapting UF/DF strategies for development\, scale‑up\, and manufacturing \nWhether you are developing next‑generation mAbs or scaling existing programs to higher concentrations\, this session will provide practical insights to help you build more robust\, repeatable UF/DF processes for the high‑concentration era.
URL:https://thebiocalendar.com/event/the-shift-to-high-concentration-mabs-3-critical-uf-df-challenges-and-how-to-solve-them/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/05-04-26-Repligen-Linkedin-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260504T130000
DTEND;TZID=America/Los_Angeles:20260504T140000
DTSTAMP:20260422T122641
CREATED:20260408T190440Z
LAST-MODIFIED:20260408T190440Z
UID:10172-1777899600-1777903200@thebiocalendar.com
SUMMARY:A Novel Cell Selective Lentiviral Platform for in vivo CAR-T Engineering
DESCRIPTION:Selective gene delivery to defined cell populations using targeted lentiviral vectors (LVV) represents a promising strategy for next‑generation immunotherapies such as chimeric antigen receptor (CAR) T‑cell therapy. While conventional CAR-T cell manufacturing requires multiple ex vivo manipulation steps up to two weeks\, targeted LVVs can enable a short ex vivo manufacturing process or direct in vivo generation of functional CAR-T cells with substantial lower complexity and cost\, improving accessibility to the therapy. \nWe have developed a novel paramyxovirus (PV)‑pseudotyped LVV platform designed for efficient gene transfer into non‑activated T cells ex vivo and in vivo. In this system\, viral binding and fusion are mediated by modified hemagglutinin (H) and fusion (F) glycoproteins respectively. Mutation of H abolishes natural tropism\, while retargeting is achieved by fusing cell‑specific single‑chain variable fragments (scFvs) or heavy‑chain variable domains (VHHs)\, enabling targeted transduction. \nUsing our high titer packaging cell line and an optimized transfection process\, we produced  CD4‑\, CD8‑\, and pan‑T‑cell–specific LVV\, which efficiently generated CAR-T cells in vitro and in vivo in a PBMC-transplanted NSG mouse model. Importantly\, these CAR-T cells led to robust tumor lysis in vitro and rapid tumor B-cell depletion in vivo\, highlighting the clinical feasibility of this approach.  \nIn summary\, our optimized targeted LVV platform enables selective and rapid generation of defined CAR-T cell subsets\, providing a foundation for safe\, cost-effective and accessible CAR-T cell therapies.
URL:https://thebiocalendar.com/event/a-novel-cell-selective-lentiviral-platform-for-in-vivo-car-t-engineering/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-04-26-Miltenyi-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260505T110000
DTEND;TZID=America/Los_Angeles:20260505T120000
DTSTAMP:20260422T122641
CREATED:20260407T115320Z
LAST-MODIFIED:20260407T115320Z
UID:10138-1777978800-1777982400@thebiocalendar.com
SUMMARY:Organs-on-Chips: Tech Progress & Regulatory Tailwinds
DESCRIPTION:Microphysiological (MPS) systems are proving to be increasingly valuable for early drug discovery. By recreating human‑specific physiology—fluid flow\, barrier function\, multicellular interactions\, and organ‑level mechanics—organ‑on‑chip models generate insight that’s difficult to obtain from traditional cell lines or animals. They support target validation research and they enable early efficacy modeling for processes like neuroinflammation\, fibrosis\, barrier breakdown\, infection\, and metabolic dysfunction. Liver\, kidney\, lung\, gut\, cervix\, and BBB chips can also provide early tox\, PK/PD\, and ADME readouts; measuring metabolism\, clearance\, permeability\, and drug–drug interactions. Beyond these core areas\, chips offer windows into disease modeling\, including patient‑specific biology using iPSC‑derived cells\, and help de‑risk newer modalities that need human‑relevant microenvironments to behave predictably. Together\, these capabilities make MPS one of the most important emerging tools for building human biology into discovery from the start\, not just for avoiding late‑stage toxicology failures. \nThe panel will discuss the progress being made in these key areas and provide insight into the future of organ-on-chip model research. Register for free today.
URL:https://thebiocalendar.com/event/organs-on-chips-tech-progress-regulatory-tailwinds/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/26_05_DDO_HTML_600x300.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T090000
DTEND;TZID=America/Los_Angeles:20260506T100000
DTSTAMP:20260422T122641
CREATED:20260408T172304Z
LAST-MODIFIED:20260408T172304Z
UID:10158-1778058000-1778061600@thebiocalendar.com
SUMMARY:Outsourcing Must Haves in 2026: Regional Supply Chain Strategy & Capacity – Top Experts and CDMO CEOs on Actionable Strategies
DESCRIPTION:Explore why regional supply chain diversification and strong CDMO partnerships are no longer optional\, but essential for resilience\, speed\, and compliance in 2026. Hear directly from top industry experts and CDMO leaders as they share actionable strategies\, real-world insights\, and urgent steps companies must take to secure capacity\, reduce risk\, and stay competitive.
URL:https://thebiocalendar.com/event/outsourcing-must-haves-in-2026-regional-supply-chain-strategy-capacity-top-experts-and-cdmo-ceos-on-actionable-strategies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/Biocal-14.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T110000
DTEND;TZID=America/Los_Angeles:20260506T170000
DTSTAMP:20260422T122641
CREATED:20260407T130644Z
LAST-MODIFIED:20260407T130645Z
UID:10142-1778065200-1778086800@thebiocalendar.com
SUMMARY:Reliable and comprehensive control in bioprocessing: Substrate\, metabolite and product analysis at one device
DESCRIPTION:In bio-process control\, including mammalian cell cultures as well as microbial fermentation\, Cedex Analyzers from Roche CustomBiotech enable fast and reliable determination of the relevant media components\, for optimization of the protocols and for monitoring of routine processes to achieve optimal yield and product quality. \nMore than 30 parameters can be analyzed on the same device\, including common culture control parameters like glucose\, glutamine\, lactate\, ammonia\, osmolality\, as well as typical products like monoclonal antibodies and modified variants thereof\, and also many special parameters required to be controlled in various applications\, (e.g. Ala-Gln\, Asn\, iron\, phosphate\, acetate\, glycerol\, methanol\, optical density\, …). \nFurthermore\, there are options provided for integration of the Cedex Analyzers in automated workflows\, for example with numerous small-scale bioreactors in the process development\, or with bio-manufacturing in high-scale fermenters in pharmaceutical or industrial biotech environments. \nKey learning objectives:\n    Learn about improving product yield and quality in culture-based bio-manufacturing\n    Get an overview of the available Cedex Analyzers test menu including latest extensions\n    See examples of Cedex Analyzer applications in pharmaceutical and industrial bio-processing
URL:https://thebiocalendar.com/event/reliable-and-comprehensive-control-in-bioprocessing-substrate-metabolite-and-product-analysis-at-one-device/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-06-26-Roche-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260507
DTEND;VALUE=DATE:20260509
DTSTAMP:20260422T122641
CREATED:20260327T140922Z
LAST-MODIFIED:20260327T140922Z
UID:10108-1778112000-1778284799@thebiocalendar.com
SUMMARY:The Convergence Forum
DESCRIPTION:What opportunities get created as fields converge? What challenges surface as markets\, policies\, and investing dynamics shift? What new scientific discoveries are potential game-changers? Convergence exists to explore those questions (and many others)\, with a high-level audience interested in what’s happening in the rapidly-converging worlds of biotech\, pharma\, healthcare\, medical devices\, and the Internet. \nThe Convergence Forum fosters real debate and discussion among audiences that are every bit as high-level as the speakers. The programs provide an opportunity for participants to make important new contacts\, do business\, explore important new directions in research\, delve deeply into what it takes to maintain competitive advantage in a fast-changing world\, and leave feeling recharged.
URL:https://thebiocalendar.com/event/the-convergence-forum-2/
LOCATION:Cape Cod\, Harwich\, MA\, 02645\, United States
CATEGORIES:Forum
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260507T100000
DTEND;TZID=America/Los_Angeles:20260507T120000
DTSTAMP:20260422T122641
CREATED:20260327T122537Z
LAST-MODIFIED:20260327T122537Z
UID:10092-1778148000-1778155200@thebiocalendar.com
SUMMARY:Smart Sourcing: IRT/RTSM Technology Showcase
DESCRIPTION:Join us for a virtual expo built for clinical teams that need to evaluate Interactive Response Technology / Randomization & Trial Supply Management platforms.  \nSelecting the right supplier is a vital decision that impacts patient safety\, data integrity\, and site compliance.  \nThe Clinical Leader Solutions Expo is designed to support clinical research experts in accelerating their decision-making process. \nWhat to expect:\n✔ Live 15-minute product based presentations from leading IRT/RTSM vendors\n✔ Side-by-side comparisons. See real-world capabilities.\n✔ Real-time Q&A with each presenter.\n✔ Get the insights that matter to your team
URL:https://thebiocalendar.com/event/smart-sourcing-irt-rtsm-technology-showcase/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/05-07-2026-CLSE-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260507T110000
DTEND;TZID=America/Los_Angeles:20260507T120000
DTSTAMP:20260422T122641
CREATED:20260408T172649Z
LAST-MODIFIED:20260408T172653Z
UID:10162-1778151600-1778155200@thebiocalendar.com
SUMMARY:Early Developability Assessment for Antibody Based Therapeutics
DESCRIPTION:Discover how integrated in silico and in vitro approaches can assess developability\, manufacturability\, and immunosafety at the earliest stages. Learn how a toolbox strategy enables smarter candidate selection\, reduces downstream risk\, and supports faster progression of multi-specific antibodies into clinical development. \nKey takeaways include:\n– Early identification of developability and immunosafety risks in multi-specific antibodies\n– How combined in silico and in vitro screening improves lead selection\n– Strategies to enhance manufacturability and product quality from the start\n– Using a toolbox approach to streamline development and accelerate timelines
URL:https://thebiocalendar.com/event/early-developability-assessment-for-antibody-based-therapeutics/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-07-26-Lonza-eBlast-700x200-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260507T130000
DTEND;TZID=America/Los_Angeles:20260507T140000
DTSTAMP:20260422T122641
CREATED:20260402T160919Z
LAST-MODIFIED:20260402T160920Z
UID:10129-1778158800-1778162400@thebiocalendar.com
SUMMARY:How to Activate Industrial AI Under GxP\, Governance\, and Security Constraints
DESCRIPTION:This webinar invites an interactive dialogue to explore how Industrial AI can be introduced where plants are today. We’ll walk through what is real and working now to turn insights into governed\, auditable actions\, with human oversight by design.
URL:https://thebiocalendar.com/event/how-to-activate-industrial-ai-under-gxp-governance-and-security-constraints/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-07-26-Siemens-Reg-Banner-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260507T163000
DTEND;TZID=America/New_York:20260507T190000
DTSTAMP:20260422T122641
CREATED:20260415T164149Z
LAST-MODIFIED:20260415T164149Z
UID:10206-1778171400-1778180400@thebiocalendar.com
SUMMARY:JLL & BVS’ Spring Community Celebration in Tarrytown\, New York
DESCRIPTION:BVS in collaboration with JJL is excited to host our first indoor JLL & BVS’ Spring Community Celebration in Tarrytown. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nWe invite all entrepreneurs\, researchers\, and scientists from institutes\, biotech firms\, and other companies in Tarrytown and the surrounding areas to join us for this event. This gathering brings together professionals from the healthcare\, biotech\, academic\, and local business communities for networking\, collaboration\, and knowledge sharing. \n✨ What to Expect: \n    Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n    Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n    Lab Tours: Take a tour of the lab space available at 500 White Plains Road\n    Delicious Appetizers & Drinks: Enjoy delicious spring-inspired appetizers\, craft beer\, wine and the “Westchester Spring Spritz” Prosecco cocktail\, as you network and explore the vendor exhibits. \nAdmission Details: \n    FREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n    $200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there!
URL:https://thebiocalendar.com/event/jll-bvs-spring-community-celebration-in-tarrytown-new-york-2/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-7-26-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260508T110000
DTEND;TZID=America/Los_Angeles:20260508T120000
DTSTAMP:20260422T122641
CREATED:20260408T173023Z
LAST-MODIFIED:20260408T173023Z
UID:10168-1778238000-1778241600@thebiocalendar.com
SUMMARY:From Insights to Impact: Predictive Models and PAT for More Efficient and Robust Biologics Manufacturing
DESCRIPTION:Explore how data-driven tools and Process Analytical Technology (PAT) can optimize scale-up\, enhance process control\, and reduce risk from cell culture through drug product. Learn how integrating advanced modeling and real-time monitoring enables more reliable\, cost-effective\, and scalable biologics production. \nKey takeaways include:\n– Applying predictive\, engineering-driven models to improve bioreactor scale-up and performance\n– Using mechanistic models and data to enable robust tech transfer and process optimization\n– Leveraging PAT tools for real-time monitoring\, adaptive control\, and process stability\n– Scaling lyophilization with design space approaches to ensure product quality and consistency\n– Reducing scale-up uncertainty and accelerating path to commercial manufacturing
URL:https://thebiocalendar.com/event/from-insights-to-impact-predictive-models-and-pat-for-more-efficient-and-robust-biologics-manufacturing/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-08-26-Lonza-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260511
DTEND;VALUE=DATE:20260516
DTSTAMP:20260422T122641
CREATED:20251206T101044Z
LAST-MODIFIED:20251206T101044Z
UID:9623-1778457600-1778889599@thebiocalendar.com
SUMMARY:ASGCT Annual Meeting
DESCRIPTION:The ASGCT Annual Meeting is the leading global event for professionals in gene and cell therapy\, hosted by the American Society of Gene + Cell Therapy (ASGCT) to showcase cutting-edge research\, new technologies\, and clinical applications\, offering crucial networking for scientists\, industry leaders\, and clinicians to advance treatments for human diseases. It features expert presentations\, novel abstract presentations\, workshops\, and exhibitions from companies in the cell and gene therapy ecosystem.
URL:https://thebiocalendar.com/event/asgct-annual-meeting/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Academic Research,Networking,Presentation
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260511
DTEND;VALUE=DATE:20260516
DTSTAMP:20260422T122641
CREATED:20251206T101440Z
LAST-MODIFIED:20260116T121409Z
UID:9625-1778457600-1778889599@thebiocalendar.com
SUMMARY:PEGS Boston
DESCRIPTION:The PEGS Boston Summit is where the future of biologics takes shape. For over 20 years\, PEGS is the go-to event for protein and antibody engineering\, drug development\, immunotherapy\, radiotherapy\, and AI/ML-driven biologics research. New in 2026: a dedicated focus on peptides\, spotlighting their therapeutic power\, design innovations\, and expanding role in drug discovery. \nWith 350+ presentations\, breakout sessions\, and interactive training seminars\, PEGS delivers the insights and connections you need to stay ahead. The exhibit hall buzzes with top technology and service providers\, giving you a front-row seat to the tools transforming the industry. \nDon’t just follow the science – be part of it. Join us at the 2026 PEGS Boston Summit and connect with the leaders shaping what’s next in biologics and beyond.
URL:https://thebiocalendar.com/event/pegs-boston-3/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Featured,Summit
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/12/pegs2026-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260511T080000
DTEND;TZID=America/Los_Angeles:20260514T170000
DTSTAMP:20260422T122641
CREATED:20251206T100827Z
LAST-MODIFIED:20251206T100827Z
UID:9622-1778486400-1778778000@thebiocalendar.com
SUMMARY:AAPS National Biotechnology Conference
DESCRIPTION:The AAPS National Biotechnology Conference (NBC) is a premier annual event by the American Association of Pharmaceutical Scientists (AAPS) for leaders in pharma and biotech to explore cutting-edge science in biologics\, advanced therapies\, and innovative drug development\, focusing on new modalities like CAR-T\, gene therapies\, and AI in drug discovery\, bridging research from lab to patient. It features scientific sessions\, poster presentations\, and networking opportunities\, addressing challenges in formulation\, bioanalysis\, manufacturing\, and translational science for complex drugs
URL:https://thebiocalendar.com/event/aaps-national-biotechnology-conference/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Academic Research,Summit,Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260511T110000
DTEND;TZID=America/Los_Angeles:20260511T120000
DTSTAMP:20260422T122641
CREATED:20260410T130948Z
LAST-MODIFIED:20260410T130948Z
UID:10185-1778497200-1778500800@thebiocalendar.com
SUMMARY:Design scalable downstream processes with practical purification and analytical strategies
DESCRIPTION:Downstream process development is rapidly evolving as new modalities\, from mAbs to mRNA\, viral vectors\, and other complex molecules\, enter development pipelines. This webinar will share practical strategies and analytical considerations for designing robust\, scalable purification processes across diverse molecule types. \nDrawing on decades of chromatography innovation and the expertise of our global Fast Trak™ process development (PD) teams\, Cytiva speakers will show how we use tools such as our Biacore™ surface plasmon resonance (SPR) system and size-exclusion chromatography with multi-angle light scattering (SEC-MALS) to clarify complex mechanisms\, address unpredictable impurities\, and overcome challenges that traditional approaches cannot resolve. \nYou will also hear how the combination of this experience\, advanced analytics\, and focused knowledge transfer can accelerate development\, reduce risk\, and help customers build lasting internal capability and true process ownership. \nUsing case examples spanning proteins\, antibodies\, nucleic acids\, viruses\, and vesicles\, we will feature common downstream pitfalls and highlight how our integrated chromatography and analytical strengths help avoid them. Whether you are advancing proof of concept or preparing to scale up\, you will leave with a clear view of how Cytiva PD\, SPR\, and chromatography leadership enables efficient\, confident downstream development—even for the most complex modalities. \nKey Learning Objectives: \n    Learn practical\, scalable approaches for developing chromatography‑based purification processes\n    Understand how advanced analytical tools such as SPR (Biacore™ system) and SEC‑MALS reveal complex molecular interactions and impurity mechanisms\n    Explore how combining chromatography expertise\, advanced analytics\, and structured knowledge transfer accelerates development and builds long‑term process capability
URL:https://thebiocalendar.com/event/design-scalable-downstream-processes-with-practical-purification-and-analytical-strategies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-11-26-Cytiva-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260515
DTSTAMP:20260422T122641
CREATED:20260330T202508Z
LAST-MODIFIED:20260330T202508Z
UID:10116-1778544000-1778803199@thebiocalendar.com
SUMMARY:Fierce Biotech Week
DESCRIPTION:Be in the Room Where Decisions Are Made \n\n\n\n\n\n\n\n\nFierce Biotech Week attracts senior leaders across biotech and pharma\, including: \n\n\nC-suite executives and founders \n\n\nHeads of R&D and Drug Development \n\n\nClinical & TMF leadership \n\n\nBD&L and corporate strategy teams \n\n\nPR & Communications executives \n\n\nStrategic outsourcing partners \n\n\nThis is not a spectator audience. It’s a room of decision-makers.
URL:https://thebiocalendar.com/event/fierce-biotech-week-2/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T110000
DTEND;TZID=America/Los_Angeles:20260512T120000
DTSTAMP:20260422T122641
CREATED:20260414T133825Z
LAST-MODIFIED:20260414T133825Z
UID:10194-1778583600-1778587200@thebiocalendar.com
SUMMARY:Applying AI to Study Simulation: From Design to Analysis
DESCRIPTION:AI is making it possible to simulate clinical trials before they begin using realistic synthetic patient cohorts built from real-world data. \nIn this session\, you’ll see how these simulations compare to actual Phase 2 and Phase 3 trial data\, and how teams are using them to test protocols\, reduce risk\, and improve study design faster. \nWe’ll also explore how TrialKit brings these capabilities into a single platform for simulation\, analysis\, and execution. \nYou’ll learn:\n– How synthetic patient cohorts are created and validated\n– How to simulate and refine trials before enrolling patients\n– Key considerations for applying AI in clinical research
URL:https://thebiocalendar.com/event/applying-ai-to-study-simulation-from-design-to-analysis/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Crucial-Data-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T110000
DTEND;TZID=America/Los_Angeles:20260512T120000
DTSTAMP:20260422T122641
CREATED:20260417T125535Z
LAST-MODIFIED:20260417T125535Z
UID:10222-1778583600-1778587200@thebiocalendar.com
SUMMARY:Distributed Manufacturing for CGT: Rent\, Lease\, or Buy in an Era of Overcapacity?
DESCRIPTION:As cell and gene therapy companies navigate the 2026 landscape marked by manufacturing overcapacity\, a strategic question is no longer if to outsource\, but how.  \nFor leaders across MSAT\, CMC\, and technical operations\, the choice between renting\, leasing\, or building distributed manufacturing capabilities has direct implications for speed to clinic\, capital efficiency\, and long-term scalability. Critically\, many organizations still face a persistent gap in generating high-quality IND-enabling material early\, an issue that can delay clinical entry and jeopardize key funding milestones.  \nIn this Cell & Gene Live\, Chief Editor Erin Harris will be joined by Sugu Patro\, Ph.D.\, SVP Global Process Development\, at Kite Pharma and Emily Moran\, Founder and Principal of 3LB Consulting\, who will unpack what biotech teams should prioritize when evaluating partners in an overcapacity market\, how to align early manufacturing strategy with clinical and financial goals. They will also share lessons to be drawn from Kite’s in-house expertise to build more resilient\, future-ready manufacturing models.
URL:https://thebiocalendar.com/event/distributed-manufacturing-for-cgt-rent-lease-or-buy-in-an-era-of-overcapacity/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/26_05_CGL_LinkedIn_1280x720.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T130000
DTEND;TZID=America/Los_Angeles:20260512T140000
DTSTAMP:20260422T122641
CREATED:20260413T161457Z
LAST-MODIFIED:20260413T161458Z
UID:10190-1778590800-1778594400@thebiocalendar.com
SUMMARY:Don’t Sacrifice Compliance: Strategies for Audit-Ready System Integrations
DESCRIPTION:Discover how modern integration strategies are enabling companies to bridge critical systems\, streamline data flow\, and maintain regulatory confidence that supports innovation and compliance\, so your systems evolve as fast as your business.
URL:https://thebiocalendar.com/event/dont-sacrifice-compliance-strategies-for-audit-ready-system-integrations/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Blue-Mountain-Reg-1920x250-rev.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260514T110000
DTEND;TZID=America/Los_Angeles:20260514T120000
DTSTAMP:20260422T122641
CREATED:20260409T125450Z
LAST-MODIFIED:20260409T125450Z
UID:10176-1778756400-1778760000@thebiocalendar.com
SUMMARY:AI Meets Informed Consent: Opportunity\, Risk\, and What IRBs Need to See
DESCRIPTION:The informed consent process is an ongoing dialogue that helps participants decide\, with full understanding\, whether to take part in a clinical trial. As generative AI begins to influence how consent documents are created\, translated\, and delivered\, this process is becoming more complex. \nJoin experts in IRB oversight\, research ethics\, and health literacy to explore the opportunities and challenges of AI-assisted informed consent. This session will cover ethical foundations\, emerging use cases for generative AI\, and what sponsors and CROs need to communicate to IRBs when using these tools. \nDesigned for clinical operations leaders across biopharma\, medtech\, and CROs\, this discussion will provide a practical framework for evaluating AI-driven consent approaches while keeping patient understanding and protection at the center.
URL:https://thebiocalendar.com/event/ai-meets-informed-consent-opportunity-risk-and-what-irbs-need-to-see/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Brany-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260514T110000
DTEND;TZID=America/Los_Angeles:20260514T120000
DTSTAMP:20260422T122641
CREATED:20260416T190955Z
LAST-MODIFIED:20260416T190955Z
UID:10214-1778756400-1778760000@thebiocalendar.com
SUMMARY:Strategic Early Material Generation for Accelerated Process Development
DESCRIPTION:Accelerate biologics development by enabling rapid access to scalable\, production-relevant early-stage material that supports developability assessment and process optimization. This webinar highlights Samsung Biologics’ integrated approach\, aligning material generation with cell line development\, incorporating early optimization\, and leveraging stable expression platforms to deliver consistent\, high-quality material with reduced variability. Learn how this streamlined strategy shortens timelines\, simplifies processes\, and improves resource efficiency\, supported by case studies demonstrating successful scale-up from flask to bioreactor. \nKey Takeaways:\n– The role of early material generation in enabling efficient biologics development and early developability assessment\n– How aligning material generation with cell line development supports both speed and scalability from early stages\n– How scalable\, production-relevant material supports process development activities\, including formulation studies and other material-intensive applications\, while improving overall time and resource efficiency
URL:https://thebiocalendar.com/event/strategic-early-material-generation-for-accelerated-process-development/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-Samsung-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260514T110000
DTEND;TZID=America/Los_Angeles:20260514T120000
DTSTAMP:20260422T122641
CREATED:20260416T191238Z
LAST-MODIFIED:20260416T191238Z
UID:10218-1778756400-1778760000@thebiocalendar.com
SUMMARY:Understanding the Regulatory Landscape for Ophthalmic Drug Products: Contamination Control Strategies\, USP \, and Purpose-Built Solutions
DESCRIPTION:Navigate the increasingly complex regulatory landscape for ophthalmic drug products by understanding key standards such as USP  and EU GMP Annex 1\, and how they drive the need for robust Contamination Control Strategies (CCS). This webinar explores how developers can address real-world manufacturing and compliance challenges while improving product quality and patient safety through purpose-built packaging and delivery solutions. \nKey takeaways:\n– Develop an effective Contamination Control Strategy (CCS)\n– Differentiate the regulatory requirements for ophthalmic drug products compared with standard injectables\n– Interpret USP  particle limits and their implications for intraocular drug administration\n– Evaluate available solutions that support ophthalmic drug delivery
URL:https://thebiocalendar.com/event/understanding-the-regulatory-landscape-for-ophthalmic-drug-products-contamination-control-strategies-usp-and-purpose-built-solutions/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-14-26-West-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260422T122641
CREATED:20251206T101304Z
LAST-MODIFIED:20251206T101316Z
UID:9624-1779148800-1779407999@thebiocalendar.com
SUMMARY:Bio-IT Conference & Expo
DESCRIPTION:The Bio-IT World Conference & Expo is the premier global event showcasing technologies and analytic approaches that solve problems\, accelerate science\, and drive the future of precision medicine. Now in its 25th year\, the event convenes more than 2\,900 leaders from biopharma\, clinical research\, healthcare\, informatics\, and technology to exchange ideas\, showcase solutions\, and spark collaborations that push the boundaries of biomedical research\, drug discovery\, and patient outcomes. Spanning 200+ sessions—including plenary keynotes\, symposia\, technical workshops\, and hands-on demonstrations—Bio-IT World offers unmatched opportunities to explore the tools\, platforms\, and strategies redefining R&D and clinical care. From AI\, generative AI\, and machine learning to multimodal and real-world data strategies\, FAIR/Open Source practices\, pilot programs\, new product launches\, and biotech investment trends\, attendees engage in transformative conversations that translate innovation into measurable value. \nAt its core\, Bio-IT World is more than a conference—it is a community driving discovery\, accelerating science\, and shaping the conversations that define the next era of precision medicine.
URL:https://thebiocalendar.com/event/bio-it-conference-expo-2/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Expo
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260422T122641
CREATED:20260420T150251Z
LAST-MODIFIED:20260420T150251Z
UID:10232-1779148800-1779407999@thebiocalendar.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:Returning for its 8th year\, LEAP HR: Life Sciences West reunites 100+ senior HR leaders from scaling and stabilizing biotech organizations to uncover how to navigate volatility\, unlock peer-led insights\, and deliver tangible business impact. \nAcross three days of high-impact content\, you’ll gain actionable takeaways through case studies\, benchmarking sessions\, structured networking\, roundtable discussions\, and speed learning. From navigating immigration shifts and political change to building lean HR functions and retaining talent in a competitive market\, this is the only forum dedicated to tackling the unique people challenges facing West Coast life sciences organizations. \nJoin us this May to connect with forward–thinking HR leaders and discover how to lead with clarity\, creativity\, and confidence in a rapidly evolving operating environment.
URL:https://thebiocalendar.com/event/leap-hr-life-sciences-west-2/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Forum,Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260422T122641
CREATED:20260227T112059Z
LAST-MODIFIED:20260228T120528Z
UID:9981-1779148800-1779407999@thebiocalendar.com
SUMMARY:Health & Business Growth Summit Zagreb
DESCRIPTION:Health & Business Growth Summit Zagreb 2026 is an international event that brings together experts\, entrepreneurs\, and innovators from the healthcare and business sectors. Over the course of three days\, the summit features a combination of inspiring keynote talks\, panel discussions\, an exhibition area\, and networking opportunities\, all focused on development\, growth\, and global expansion of healthtech and medtech solutions. The goal of the summit is to connect leading professionals\, investors\, hospitals\, insurers\, and entrepreneurs\, and to encourage the creation of new partnerships\, funding opportunities\, and business advancement. \nThe Health & Business Growth Summit is the first event of its kind in Croatia\, designed to position Zagreb as a CEE gateway\, bridging regional innovators and advanced European healthcare ecosystems. \nThe summit is organized by Proqlea\, a Zagreb-based pharmaceutical company specialized in CRO services and regulatory consulting. Our goal is to create an international platform connecting healthcare entrepreneurs\, innovators\, MedTech startups\, investors\, and support institutions through: \n– Inspirational keynote lectures\n– Dynamic panel discussions\n– Exhibition space\n– Exclusive VIP networking\n– Pitch sessions organized by NetHub \nWe place special emphasis on young entrepreneurs\, startups\, and SMEs\, providing them with key information and contacts for growth and entry into foreign markets\, as well as facilitating the entry of international entrepreneurs into Croatia.
URL:https://thebiocalendar.com/event/health-business-growth-summit-zagreb/
LOCATION:Zagreb\, Zagreb\, Zagreb\, 10000\, Croatia (Local Name: Hrvatska)
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260519T110000
DTEND;TZID=America/Los_Angeles:20260519T120000
DTSTAMP:20260422T122641
CREATED:20260422T125020Z
LAST-MODIFIED:20260422T125020Z
UID:10245-1779188400-1779192000@thebiocalendar.com
SUMMARY:From Protocol to Patient Risk: How to Build Safer\, Faster Trials by Integrating Clinical Operations and Pharmacovigilance Early
DESCRIPTION:Clinical execution and pharmacovigilance are often managed in parallel rather than in partnership. For sponsors\, that disconnect can create avoidable delays\, inconsistent safety decision-making\, protocol amendments\, and added pressure on sites and study teams. In early-phase and complex trials\, where risk profiles are still emerging\, these gaps can have a direct impact on both patient safety and development timelines. \nJoin experts from Ergomed Clinical Research and PrimeVigilance for a practical discussion on how earlier integration across clinical operations\, medical monitoring\, and pharmacovigilance can strengthen study oversight from the outset. This webinar will examine where silos tend to emerge\, how integrated planning can reduce downstream issues\, and what sponsors can do to build a more connected model across protocol strategy\, trial conduct\, individual case safety report handling\, and signal and risk management. \nAttendees will gain practical insight into how a more aligned clinical and safety strategy can support better benefit-risk decisions\, reduce operational risk\, and help keep complex studies on track. \nKey Takeaways:\n– Why separating clinical operations and safety oversight creates avoidable risk in clinical development\n– Where silos most often create issues\, including delayed decisions\, protocol amendments\, inconsistent safety data handling incl. signal and risk management\, and added site burden\n– What integrated planning and execution looks like in practice across study design\, medical monitoring\, pharmacovigilance\, and trial conduct\n– How earlier collaboration can support stronger decision-making\, operational readiness\, and timeline protection\n– Practical ways to reduce downstream risk while improving both patient safety and study efficiency
URL:https://thebiocalendar.com/event/from-protocol-to-patient-risk-how-to-build-safer-faster-trials-by-integrating-clinical-operations-and-pharmacovigilance-early/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-19-26-Ergomed-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260520T130000
DTEND;TZID=America/Los_Angeles:20260520T140000
DTSTAMP:20260422T122641
CREATED:20260421T103753Z
LAST-MODIFIED:20260421T103753Z
UID:10233-1779282000-1779285600@thebiocalendar.com
SUMMARY:Cleanroom ISO Classification: The Framework for Containment in a Cleanroom
DESCRIPTION:Cleanroom ISO classification is a foundational decision that directly impacts facility design\, GMP manufacturing operations\, and regulatory outcomes in biotech and pharmaceutical environments. This is especially critical in cell and gene therapy\, viral vector\, API\, mRNA\, and sterile ATMP manufacturing\, where product protection\, biohazard containment\, and operator safety must be carefully balanced. \nIn this webinar\, we’ll explore how ISO classification strategy shapes key aspects of cleanroom design\, including process layout\, HVAC system design\, air change rates\, pressurization schemes\, and airlock sequencing in Biosafety Level and OEB-driven environments. \nAttendees will learn why early alignment between process operations\, containment strategy\, and regulatory expectations is essential when working with biohazardous materials\, high-potency compounds\, and patient-specific therapies. Without this alignment\, organizations risk costly redesigns\, operational inefficiencies\, and compliance challenges. \nWe’ll also examine how misaligned classification decisions can limit manufacturing flexibility\, increase operator exposure risk\, and weaken containment strategies. \nDrawing on real-world project experience across viral vector and cell processing facilities\, this session will demonstrate how integrating ISO classification into early design phases supports effective containment\, cross-contamination control\, and inspection readiness. The webinar will emphasize practical approaches to aligning cleanroom infrastructure with process needs to help you build safe\, compliant\, and scalable ATMP manufacturing operations that meet both current and future goals. \nKey Learning Objectives:\n–   Understand how ISO classification drives cleanroom containment\, HVAC system approach\, pressurization strategies\, airlock scheme\, and GMP manufacturing quality\n –  Identify compliance\, cross-contamination and operational risks caused by misaligned ISO classification strategies in ATMP manufacturing cleanrooms\n –  Recognize the relationship between process operations\, contamination risk\, and ISO classification selection through early planning to support inspection readiness
URL:https://thebiocalendar.com/event/cleanroom-iso-classification-the-framework-for-containment-in-a-cleanroom/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-20-26-AES-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260520T160000
DTEND;TZID=America/Los_Angeles:20260520T183000
DTSTAMP:20260422T122641
CREATED:20260415T163842Z
LAST-MODIFIED:20260415T163842Z
UID:10202-1779292800-1779301800@thebiocalendar.com
SUMMARY:BVS' Biotech Community Event at Biovista\, San Diego
DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at the Biovista Life Science Campus. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \n✨ What to Expect: \n    Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n    Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n    Delicious Appetizers by California English & Drinks: Enjoy delicious appetizers as you network and explore the vendor exhibits. \nWe are inviting all the tenants and all local life science researchers and entrepreneurs in the surrounding area to attend. \nAdmission Details:\nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, non-sales/bus dev positions etc.) from life science companies and research institutes.\n$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there!
URL:https://thebiocalendar.com/event/bvs-biotech-community-event-at-biovista-san-diego-3/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/04/BVS-Biotech-Event-Flyer-05-20-26.jpg
END:VEVENT
END:VCALENDAR